rac-(4aR,7aS)-hexahydro-2H-furo[3,4-b]morpholinehydrochloride,trans | 1616434-92-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: rac-(4aR,7aS)-hexahydro-2H-furo[3,4-b]morpholinehydrochloride,trans
• 英文别名: (4aS,7aR)-3,4,4a,5,7,7a-hexahydro-2H-furo[3,4-b][1,4]oxazine;hydrochloride
• CAS: 1616434-92-4
• 化学式: C₆H₁₁NO₂*ClH
• 分子量: 165.62
• InChiKey: CBCKFSNBSXRTCT-GEMLJDPKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  30.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-6-(3-fluoropyridin-4-yl)-3-methylpyrimidin-4(3H)-one 、 rac-(4aR,7aS)-hexahydro-2H-furo[3,4-b]morpholinehydrochloride,trans 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 2-[(4aS,7aR)-2,3,4a,5,7,7a-hexahydrofuro[3,4-b][1,4]oxazin-4-yl]-6-(3-fluoropyridin-4-yl)-3-methylpyrimidin-4-one
  参考文献：
  名称：

  Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3β inhibitors for Alzheimer’s disease

  摘要：

  We herein describe the results of further evolution of GSK-3 beta inhibitors for Alzheimer's disease from our promising compounds with in vivo tau phosphorylation inhibitory activity by oral administration. Introduction of a low alkyl group instead of the phenyl group at the 3-position of the morpholine moiety aiming to improve pharmacokinetic profiles resulted in potent low molecular weight GSK-3 beta inhibitors with good in vitro pharmacokinetic profiles, which also showed in vivo tau phosphorylation inhibitory activity by oral administration. Effect of the stereochemistry of the alkyl moiety is also discussed using docking models. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.01.005